Modality
Fusion Protein
MOA
PD-L1i
Target
HER2
Pathway
Apoptosis
Heart Failure
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Aug 2027
Phase 2Current
NCT04440389
1,077 pts·Heart Failure
2023-09→TBD·Not yet recruiting
NCT05764770
2,555 pts·Heart Failure
2021-04→2027-08·Recruiting
3,632 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-08-251.4y awayPh2 Data· Heart Failure
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2027-08-25 · 1.4y away
Heart Failure
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04440389 | Phase 2 | Heart Failure | Not yet recr... | 1077 | LiverFat |
| NCT05764770 | Phase 2 | Heart Failure | Recruiting | 2555 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |